CRBP.US Corbus Pharmaceuticals Holding

Healthcare Biotechnology USA Stocks
3.39 USD
Close of Nov 14, 2026
2.81 12.88
Market cap
USD 69.9M
P/E
-
P/B
0.83x
ROE
-150.6%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is CRBP.US undervalued?

Graham number

The Graham number of Corbus Pharmaceuticals Holding cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Corbus Pharmaceuticals Holding fundamental analysis

No fundamental analysis for Corbus Pharmaceuticals Holding yet.

Corbus Pharmaceuticals Holding stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Corbus Pharmaceuticals Holding

Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity. The company was incorporated in 2009 and is headquartered in No…

Full company profile